Biodexa Pharmaceuticals (BDRX) Assets Average (2014 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Assets Average of $22.0 million for Q4 2025, up 13.45% sequentially from $19.4 million in Q2 2025, and up 20.1% YoY from $18.3 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Assets Average (2014 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Assets Average for 12 years, with the latest figure at $22.0 million in Q4 2025.
- Quarterly Assets Average rose 20.1% year-over-year to $22.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.0 million (up 20.1% YoY) and the FY2025 annual result came in at $21.5 million, up 33.84% from the prior year.
- Assets Average rose to $22.0 million in Q4 2025 per BDRX's latest filing, from $19.4 million in the prior quarter.
- Over five years, Assets Average peaked at $22.0 million in Q4 2025 and troughed at $8.2 million in Q2 2023.
- A 5-year average of $15.2 million and a median of $15.1 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2021 and 2024: Assets Average sank 55.09% in 2021, then soared 86.79% in 2024.
- Over 5 years, Assets Average stood at $12.3 million in 2021, then increased by 20.67% to $14.8 million in 2022, then decreased by 22.14% to $11.5 million in 2023, then jumped by 58.81% to $18.3 million in 2024, then gained by 20.1% to $22.0 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $22.0 million, $19.4 million, and $18.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 21.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.98 Mn |
| Jun 30, 2025 | 19.37 Mn |
| Dec 31, 2024 | 18.30 Mn |
| Jun 30, 2024 | 15.36 Mn |
| Dec 31, 2023 | 11.52 Mn |
| Jun 30, 2023 | 8.22 Mn |
| Jun 30, 2022 | 14.80 Mn |
| Jun 30, 2021 | 12.26 Mn |
| Jun 30, 2020 | 27.31 Mn |
| Dec 31, 2019 | 38.21 Mn |
| Jun 30, 2019 | 31.51 Mn |
| Dec 31, 2018 | 37.57 Mn |
| Jun 30, 2018 | 57.10 Mn |
| Dec 31, 2017 | 61.61 Mn |
| Jun 30, 2017 | 64.17 Mn |
| Dec 31, 2016 | 75.89 Mn |
| Jun 30, 2016 | 89.24 Mn |
| Dec 31, 2015 | 85.56 Mn |
| Dec 31, 2014 | 41.16 Mn |